metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
Extensive stage SCLC (Es-SCLC) - maintenance (M) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - maintenance (M)
versus placebo
	nivolumab alone
	CheckMate 451 (N ; all population), 2019 Annals of Oncology 30 : ii77–ii80, 2019 J Clin Oncol 2021 Mar 8;JCO2002212. NCT02538666	RCT	Extensive stage SCLC (Es-SCLC) - maintenance (M)	nivolumab	placebo	patients with extensive-stage disease small cell lung cancer (ED-SCLC) as maintenance therapy after completion of platinum-based chemotherapy	280 / 275	some concern	inconclusive	suggested 33 % decrease in progression or deaths (PFS)
	nivolumab plus ipilimumab
	CheckMate 451 (NI ; all population), 2019 Annals of Oncology 30 : ii77–ii80, 2019 NCT02538666	RCT	Extensive stage SCLC (Es-SCLC) - maintenance (M)	nivolumab plus ipilimumab	placebo	patients with extensive-stage disease small cell lung cancer (ED-SCLC) as maintenance therapy after completion of platinum-based chemotherapy	279 / 275	some concern	inconclusive	inconclusive 8 % decrease in deaths (OS) (PE) suggested 28 % decrease in progression or deaths (PFS)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
versus etoposide plus platin
	durvalumab plus etoposide and platin
	CASPIAN (D ; all population), 2019 Lancet 2019; 394:1929-1939 Lancet December 04, 2020 ESMO Open 2022 Apr;7(2):100408. NCT03043872	RCT	Extensive stage SCLC (Es-SCLC) - 1st Line (L1)	durvalumab, etoposide plus either cisplatin or carboplatin	etoposide plus either cisplatin or carboplatin	adults with untreated extensive-stage small-cell lung cancer as First-line treatment	268 / 269	some concern	conclusif	demonstrated 27 % decrease in deaths (OS) (PE) suggested 25 % decrease in deaths (OS) (extension) suggested 20 % decrease in PFS (extension) suggested 22 % decrease in progression or deaths (PFS)
	durvalumab plus tremelimumab plus SoC
	CASPIAN (DT ; all population), 2019 Lancet 2019; 394:1929-1939 Lancet December 04, 2020 ESMO Open 2022 Apr;7(2):100408. NCT03043872	RCT	Extensive stage SCLC (Es-SCLC) - 1st Line (L1)	durvalumab plus tremelimumab and etoposide plus either cisplatin or carboplatin	etoposide plus either cisplatin or carboplatin	adults with untreated extensive-stage small-cell lung cancer (SCLC)	268 / 269	some concern	inconclusive	inconclusive 18 % decrease in deaths (OS) (PE)
versus placebo plus SoC
	atezolizumab plus SoC
	IMpower-133, 2018 N. Engl. J. Med. 2018; 379:2220-2229 Clin Lung Cancer 2019; 20:469-476.e1 Ann Oncol 2020 Feb;31(2):310-317. J Clin Oncol 2021 Jan 13;JCO2001055. Lung Cancer 2023; 186:107418-. NCT02763579	RCT	Extensive stage SCLC (Es-SCLC) - 1st Line (L1)	atezolizumab (as induction and maintenance therapy) plus carboplatin and etoposide	placebo plus carboplatin and etoposide	patients with extensive-Stage Small-Cell Lung Cancer who had not received previous systemic treatment	201 / 202	low	conclusif	demonstrated 30 % decrease in deaths (OS) (PE) demonstrated 23 % decrease in progression or deaths (PFS) (PE) suggested 24 % decrease in deaths (OS) (extension) suggested 23 % decrease in PFS (extension)
	ipilimumab plus SoC
	CA184-156, 2016 J. Clin. Oncol. 2016; 34:3740-3748 NCT01450761	RCT	Extensive stage SCLC (Es-SCLC) - 1st Line (L1)	Ipilimumab plus etoposide plus platine	Placebo plus etoposide plus platine	phased induction schedule followed by maintenance in patients with Extensive-Stage Small-Cell Lung Cancer (no prior systemic therapy for ED-SCLC)	566 / 566	high	inconclusive	inconclusive 6 % decrease in deaths (OS) (PE) suggested 15 % decrease in progression or deaths (PFS)
	pembrolizumab plus SoC
	KEYNOTE-604, 2020 Journal of Clinical Oncology J Clin Oncol 2020 Jul 20;38(21):2369-2379. NCT03066778	RCT	Extensive stage SCLC (Es-SCLC) - 1st Line (L1)	pembrolizumab plus etoposide plus platine	placebo plus etoposide plus platine	patients with newly diagnosed Extensive Stage Small Cell Lung Cancer	228 / 225	low	conclusif	suggested 20 % decrease in deaths (OS),deaths (OS) (PE) demonstrated 25 % decrease in progression or deaths (PFS),progression or deaths (PFS) (PE)
limited stage SCLC (ls-SCLC) - maintenance (M) limited stage SCLC (ls-SCLC) limited stage SCLC (ls-SCLC) - maintenance (M)
versus no additional treatment
	nivolumab plus ipilimumab
	STIMULI unpublished Ann Oncol. 2022 Jan;33(1):67-79 NCT02046733	RCT	limited stage SCLC (ls-SCLC) - maintenance (M)	nivolumab plus ipilimumab	no treatment added	limited stage SCLC patients who had undergone chemoradiotherapy treated as consolidation treatment	78 / 75	NA	inconclusive	inconclusive 5 % decrease in deaths (OS) (PE) inconclusive 2 % increase in progression or deaths (PFS) (PE) statistically significant 3.1-fold increase in AE (grade 3-4) The immunotherapy combination nivolumab plus ipilimumab did not significantly improve progression-free survival (PFS) or overall survival.

Extensive stage SCLC (Es-SCLC) - maintenance (M) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - maintenance (M)

Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)

limited stage SCLC (ls-SCLC) - maintenance (M) limited stage SCLC (ls-SCLC) limited stage SCLC (ls-SCLC) - maintenance (M)